Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
21%(3 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
1
7%
Ph phase_2
3
20%
Ph phase_4
7
47%
Ph phase_1
3
20%

Phase Distribution

3

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
3(21.4%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 3Large-scale testing
1(7.1%)
Phase 4Post-market surveillance
7(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(14)
Terminated(1)

Detailed Status

Completed14
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (21.4%)
Phase 23 (21.4%)
Phase 31 (7.1%)
Phase 47 (50.0%)

Trials by Status

completed1493%
terminated17%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_1

A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)

NCT02241200
completedphase_1

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

NCT03693950
completedphase_1

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

NCT02731469
terminated

Study of South African Dialysis Patients

NCT01890577
completedphase_2

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

NCT00144131
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT02241200Phase 1

A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)

Completed
NCT03693950Phase 1

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Completed
NCT02731469Phase 1

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Completed
NCT01890577

Study of South African Dialysis Patients

Terminated
NCT00144131Phase 2

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Completed
NCT00117065Phase 4

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Completed
NCT00117130Phase 4

Study to Evaluate Effectiveness of Aranesp®

Completed
NCT00261313Phase 2

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Completed
NCT00117104Phase 4

Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

Completed
NCT00117117Phase 4

A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Completed
NCT00117039Phase 4

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Completed
NCT00117078Phase 4

Aranesp® Monthly Preference Study - 2

Completed
NCT00111995Phase 4

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Completed
NCT00116701Phase 3

Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis

Completed
NCT00245895Phase 2

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15